Coronavirus vaccines compositions and method of using same
AssigneesLoyola University of Chicago, The United States of America as represented by the Secretary of Agriculture
InventorsSusan Baker, Xufang Deng, Kelly Milton Lager, Kay Faaberg, Alexandra DeVries
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.
Claims8
A vaccine composition comprising a porcine epidemic diarrhea virus (PEDV) comprising one mutation in Nsp1, two mutations in Nsp15, and one mutation in Nsp16, wherein the mutation in Nsp1 is F44A as set out in SEQ ID NO:
- 4, the Nsp15 mutations are H226A and H241A as set out in SEQ ID NO:
- 8, and the Nsp16 mutation is D129A as set out in SEQ ID NO:
- 12, wherein said vaccine composition is capable of inducing an immune response in a non-human subject.
A method of inducing an immune response associated with a PEDV comprising administering a vaccine composition to a non-human subject, said composition comprising one mutation in Nsp1, two mutations in Nsp15, and one mutation in Nsp16, wherein the mutation in Nsp1 is F44A as set out in SEQ ID NO:
- 4, the Nsp15 mutations are H226A and H241A as set out in SEQ ID NO:
- 8, and the Nsp16 mutation is D129A as set out in SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.